Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder.

Neuromyelitis optica spectrum disorder (NMOSD) is a CNS autoimmune inflammatory disease mediated by T helper 17 (Th17) and antibody responses to the water channel protein, aquaporin 4 (AQP4), and associated with astrocytopathy, demyelination and axonal loss. Knowledge about disease pathogenesis is limited and the search for new therapies impeded by the absence of a reliable animal model. In our work, we determined that NMOSD is characterized by decreased IFN-γ receptor signalling and that IFN-γ depletion in AQP4201-220-immunized C57BL/6 mice results in severe clinical disease resembling human NMOSD.

Control and accountability of controlled substance administration in the operating room.

Personnel working in the operating room complex may be at increased risk for chemical impairment. It has been proposed that this predisposition may be related to the frequency of use of controlled substances and the inadequate control over distribution of these medications, which frequently exists in the operating room. A system utilizing a pharmacy satellite in the operating room has increased the control and accountability of drug administration practices.

[Bronchial abnormalities in a clinic for respiratory diseases (author's transl)].

The frequency in bronchial abnormalities is generally underestimated. In patients of a clinic for respiratory diseases however 3% were found in those having had a bronchoscopy, a figure which has up to now not been mentioned in the literature. After discussing originating theories and classifying possibilities the observations are tabulated, and some of them introduced as representative examples.

[Treatment of chronic bronchitis with Supristol and a cotrimoxazole preparation--comparative bacteriological and clinical findings, results of a double-blind study (author's transl)].

In a randomized double-blind study on the treatment of chronic bronchitis, Supristol (co-trifamole) was compared with co-trimoxazole. 163 patients participated in the clinical trial that was performed at three different hospitals in accordance with a uniform trial plan. The microbiological investigations were done centrally at a hygiene institute for all three hospitals.